


FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D



Mean Plasma Concentration
(ng/ml)
25
20
15
10
5
0
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Time (hr)
Patch Removed

FIG. 2A



Mean Plasma Concentration (ng/ml)
0
10
20
30
40
0
4
8
12
16
20
24
Time (hours within day 7)

FIG. 2B



Mean Projected Plasma Concentration
(ng/mL)
0
10
20
30
40
50
21
22
23
24
25
26
27
28
Time (Days from First Dose)

FIG. 3



No skin irritation
Mild skin irritation
Number of subjects out of 6
0
1
2
3
4
5
6
0.17
0.5
1
2
3
Days Post Patch Removal

FIG. 4



oral
transdermal patch (larger)
transdermal patch (smaller)
Mean Plasma Donepezil Concentration (ng/ml)
0
10
20
30
40
50
60
70
0
1
2
3
4
5
6
7
Days at Steady State (Week 5)

FIG. 5A



smaller patch (n=54)
larger patch (n=55)
Oral (n=58)
Number of Subjects
0
2
4
6
8
10
12
14
16
18
4
13
17
Nausea
2
2
5
Vomiting
4
7
9
Diarrhea

FIG. 5B



Memantine salt, sodium bicarb
Memantine free base
Memantine salt, no sodium bicarb
Memantine salt, alternative to sodium bicarb
Memantine skin flux (μg/cm².hr)
Time (hr)
0
10
20
30
40
50
0
20
40
60
80
100
120
140
160

FIG. 6



Flux (μg/cm²-h)
0.0
2.0
4.0
6.0
8.0
0
50
100
150
200
Time (h)
Transdermal System with Pretreated Membrane
Transdermal System with Untreated Membrane

FIG. 7